Information Provided By: 
Fly News Breaks for August 6, 2019
PODD
Aug 6, 2019 | 05:18 EDT
Piper Jaffray analyst JP McKim raised his price target for Insulet to $160 from $130 saying the company reported "exceptionally strong" Q2 results and raised guidance for the full year. The beat was broad based, and DASH is increasing access to new patients with no upfront cost, which is leading to an acceleration in the business, McKim tells investors in a research note. He believes Insulet's share setup over the next 18 months is one of the best in med tech and keeps an Overweight rating on the name.
News For PODD From the Last 2 Days
There are no results for your query PODD
